Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moxaverine is a synthetic small molecule vasodilator and a derivative of papaverine. It acts primarily as a phosphodiesterase inhibitor, leading to smooth muscle relaxation and vasodilation. Moxaverine also improves the rheological properties of red blood cells, enhancing microcirculatory blood flow. Clinically, it has been used to increase ocular blood flow in conditions such as age-related macular degeneration and primary open angle glaucoma, and has been studied for its effects on ischemia and other vascular disorders[1][4][5]. Its mechanism involves inhibition of phosphodiesterase enzymes, which increases intracellular cyclic nucleotide levels (cAMP/cGMP), resulting in smooth muscle relaxation[1][5]. Moxaverine hydrochloride is marketed under the brand name Kollateral forte.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moxaverine.